Bank of New York Mellon Corp Sells 73,595 Shares of Biogen Inc. $BIIB

Bank of New York Mellon Corp lowered its holdings in shares of Biogen Inc. (NASDAQ:BIIB) by 8.3% in the fourth quarter, HoldingsChannel reports. The firm owned 811,106 shares of the biotechnology company’s stock after selling 73,595 shares during the period. Bank of New York Mellon Corp’s holdings in Biogen were worth $142,747,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of BIIB. Empowered Funds LLC grew its holdings in Biogen by 64.9% during the first quarter. Empowered Funds LLC now owns 7,054 shares of the biotechnology company’s stock worth $965,000 after purchasing an additional 2,777 shares during the period. Focus Partners Wealth boosted its stake in shares of Biogen by 172.2% in the first quarter. Focus Partners Wealth now owns 10,173 shares of the biotechnology company’s stock valued at $1,392,000 after buying an additional 6,436 shares during the period. Sivia Capital Partners LLC bought a new stake in shares of Biogen in the second quarter valued at approximately $216,000. Cerity Partners LLC boosted its stake in shares of Biogen by 15.3% in the second quarter. Cerity Partners LLC now owns 46,552 shares of the biotechnology company’s stock valued at $5,847,000 after buying an additional 6,184 shares during the period. Finally, NewEdge Advisors LLC boosted its stake in shares of Biogen by 13.4% in the second quarter. NewEdge Advisors LLC now owns 2,673 shares of the biotechnology company’s stock valued at $336,000 after buying an additional 316 shares during the period. Institutional investors own 87.93% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the company. Wedbush boosted their price target on Biogen from $191.00 to $196.00 and gave the company a “neutral” rating in a research note on Thursday, April 30th. Argus upgraded Biogen to a “hold” rating in a research note on Thursday, April 9th. JPMorgan Chase & Co. boosted their price objective on shares of Biogen from $175.00 to $185.00 and gave the company a “neutral” rating in a research report on Thursday, April 23rd. Oppenheimer boosted their price objective on shares of Biogen from $275.00 to $300.00 and gave the company an “outperform” rating in a research report on Thursday, May 14th. Finally, Citigroup boosted their price objective on shares of Biogen from $190.00 to $200.00 and gave the company a “neutral” rating in a research report on Friday, May 1st. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $215.81.

More Biogen News

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen’s salanersen won FDA Breakthrough Therapy Designation for SMA, with early phase 1b data suggesting meaningful motor improvements and a once-yearly dosing profile that could make the therapy stand out commercially. BIIB’s Next-Gen SMA Therapy Salanersen Wins FDA’s Breakthrough Tag
• Positive Sentiment: Biogen also highlighted progress on BIIB115 in post-gene therapy SMA, adding to investor optimism that the company has multiple shots on goal in a key neurodegeneration market. Biogen Advances BIIB115 in Post–Gene Therapy SMA: Early Signals for Long‑Term Growth
• Positive Sentiment: Biogen and UCB presented additional data on dapirolizumab pegol in lupus, showing reduced flare rates and lower steroid use, which supports the drug’s potential in a large autoimmune market. UCB and Biogen build steroid-sparing case for lupus drug
• Neutral Sentiment: Biogen is also facing legal overhang after law firms announced investor investigations and fraud-related claims, which could keep sentiment cautious even as pipeline news improves. BIIB Investors Have Opportunity to Join Biogen Inc. Fraud Investigation with the Schall Law Firm
• Neutral Sentiment: A separate investor alert from Pomerantz also flagged a claims investigation into Biogen, adding another potential risk factor, though it does not yet indicate any formal enforcement action. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. – BIIB

Biogen Stock Down 0.6%

Shares of NASDAQ:BIIB opened at $195.34 on Friday. The company has a fifty day moving average of $187.60 and a 200-day moving average of $183.33. The company has a market capitalization of $28.84 billion, a PE ratio of 20.96, a price-to-earnings-growth ratio of 1.72 and a beta of 0.20. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.41 and a current ratio of 3.06. Biogen Inc. has a 52-week low of $121.05 and a 52-week high of $205.97.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.95 by $0.62. The company had revenue of $2.48 billion during the quarter, compared to the consensus estimate of $2.29 billion. Biogen had a net margin of 13.81% and a return on equity of 12.83%. The company’s revenue for the quarter was up 1.9% compared to the same quarter last year. During the same period in the prior year, the business earned $3.02 earnings per share. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. On average, equities analysts predict that Biogen Inc. will post 14.18 EPS for the current fiscal year.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.